Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reshad, K.
Right arrow Articles by Hitomi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reshad, K.
Right arrow Articles by Hitomi, S.

Chest, Vol 88, 393-397, Copyright © 1985 by American College of Chest Physicians

ARTICLES

Treatment of malignant pleural effusion

K Reshad, K Inui, Y Takeuchi, Y Takahashi and S Hitomi

Two hundred consecutive patients with malignant pleural effusion were reviewed. The pathologic etiology of malignant pleurisy was: primary lung cancer in 123 cases; five, mesothelioma; and 72 cases secondary to metastatic tumors. Adenocarcinoma of the lung and mammary cancer were the most frequent tumors causing malignant pleural effusion. The modalities employed in local treatment consisted of thoracocentesis in 62 patients, tube thoracotomy in 111 cases with local instillation of adriamycin, MMC, CQ, 5FU, OK432 or talc. Surgical procedures including pleuropneumonectomy or reduction surgery of the tumor with decortication were performed in ten patients. Tube drainage with local instillation of drugs was more effective than thoracocentesis with or without local therapy. Excellent initial results were obtained in patients who received reduction surgery with decortication and pleurodesis. Results of cytologic investigation were positive in 157 cases (78.5 percent). The tumor cells disappeared in 79.4 percent of primary cancer pleurisy cases and 81.1 percent of patients with metastases while disappearance or significant decrease in pleural effusion following treatment was obtained in 75.2 and 77.8 percent respectively. The median survival was 11.3 months in primary cases, and 11.7 months in patients with metastases.


This article has been cited by other articles:


Home page
 Eur Respir JHome page
K. Kishi, S. Homma, S. Sakamoto, M. Kawabata, E. Tsuboi, K. Nakata, and K. Yoshimura
Efficacious pleurodesis with OK-432 and doxorubicin against malignant pleural effusions
Eur. Respir. J., August 1, 2004; 24(2): 263 - 266.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
Y. Ohta, Y. Tanaka, T. Hara, M. Oda, S.-i. Watanabe, J. Shimizu, and Y. Watanabe
Clinicopathological and biological assessment of lung cancers with pleural dissemination
Ann. Thorac. Surg., April 1, 2000; 69(4): 1025 - 1029.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H.M.W. Verheul, K. Hoekman, A.S. Jorna, E.F. Smit, and H.M. Pinedo
Targeting Vascular Endothelial Growth Factor Blockade: Ascites and Pleural Effusion Formation
Oncologist, April 1, 2000; 5(90001): 45 - 50.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by the American College of Chest Physicians.